Known targets — ChEMBL curated mechanism
GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHMGCRMMP1MMP13MMP7MMP8PTGS1PTGS2ileSpolrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.31 |
| ▸ | EYA2 | O00167 | 1/20 | 0.31 |
| ▸ | APP | P05067 | 1/20 | 0.31 |
| ▸ | ACE | P12821 | 1/20 | 0.31 |
| ▸ | CA4 | P22748 | 2/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.30 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | DRD1 | P21728 | 1/20 | 0.30 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10336315 | 0.96 | KDM4E (0.45) | KDM4EALOX15MAPTSMN1; SMN2TDP1 | |
| Silver SCHEMBL8852446 | 0.96 | KDM4E (0.45) | KDM4EALOX15MAPTSMN1; SMN2TDP1 | |
| SCHEMBL1091948 | 0.96 | KDM4E (0.50) | KDM4EALOX15MAPTSMN1; SMN2TDP1 | |
| SCHEMBL1981343 | 0.82 | KDM4E (0.38) | KDM4EALOX15MAPTSMN1; SMN2 | |
| Edetic Acid SCHEMBL8726325 | 0.81 | ALOX15 (0.48) | KDM4EALOX15MAPTSMN1; SMN2TDP1 | |
| Edetic Acid SCHEMBL2112976 | 0.81 | ALOX15 (0.44) | KDM4EALOX15MAPTSMN1; SMN2TDP1 | |
| SCHEMBL31636037 | 0.81 | TDP1 (0.45) | KDM4EALOX15MAPTSMN1; SMN2TDP1 | |
| Edetic Acid SCHEMBL5729 | 0.77 | KDM4E (0.68) | KDM4EALOX15MAPTSMN1; SMN2TDP1 | |
| Edetic Acid SCHEMBL770659 | 0.77 | KDM4E (0.68) | KDM4EALOX15MAPTSMN1; SMN2TDP1 | |
| Edetic Acid SCHEMBL5485760 | 0.74 | KDM4E (0.73) | KDM4EALOX15MAPTSMN1; SMN2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230414490-A1 | FORMULATIONS FOR PARENTERAL DELIVERY OF COMPOUNDS AND USES THEREOF | WYETH, LLC (US) | 2023-12-28 | — | — | US | claimed |
| US-20220023200-A1 | FORMULATIONS FOR PARENTERAL DELIVERY OF COMPOUNDS AND USES THEREOF | WYETH, LLC (US) | 2022-01-27 | — | — | US | claimed |
| US-20200179270-A1 | FORMULATIONS FOR PARENTERAL DELIVERY OF COMPOUNDS AND USES THEREOF | WYETH, LLC (US) | 2020-06-11 | — | — | US | claimed |
| US-10357449-B2 | — | — | 2019-07-23 | — | — | US | claimed |
| US-20160338946-A1 | FORMULATIONS FOR PARENTERAL DELIVERY OF COMPOUNDS AND USES THEREOF | WYETH, LLC (US) | 2016-11-24 | — | — | US | claimed |
| US-20150025100-A1 | FORMULATIONS FOR PARENTERAL DELIVERY OF COMPOUNDS AND USES THEREOF | PROGENICS PHARMACEUTICALS, INC. (US) | 2015-01-22 | — | — | US | claimed |
| EP-2046388-A2 | FORMULATIONS FOR PARENTERAL DELIVERY OF COMPOUNDS AND USES THEREOF | Wyeth a Corporation of the State of Delaware (US) | 2009-04-15 | — | — | EP | claimed |
| US-20080070975-A1 | Formulations for parenteral delivery of compounds and uses thereof | WYETH (US) | 2008-03-20 | — | — | US | claimed |
| WO-2008019115-A2 | FORMULATIONS FOR PARENTERAL DELIVERY OF COMPOUNDS AND USES THEREOF | WYETH (US) | 2008-02-14 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200179270-A1 | FORMULATIONS FOR PARENTERAL DELIVERY OF COMPOUNDS AND USES THEREOF | OPRL1, OPRK1, OPRM1 | KDM4E 557/4885ALOX15 1371/4885MAPT 3070/4885 |
| US-20220023200-A1 | FORMULATIONS FOR PARENTERAL DELIVERY OF COMPOUNDS AND USES THEREOF | OPRL1, OPRK1, OPRM1 | KDM4E 557/4885ALOX15 1371/4885MAPT 3070/4885 |
| US-20230414490-A1 | FORMULATIONS FOR PARENTERAL DELIVERY OF COMPOUNDS AND USES THEREOF | OPRL1, OPRK1, OPRM1 | KDM4E 557/4885ALOX15 1371/4885MAPT 3070/4885 |
| US-10357449-B2 | — | OPRL1, OPRK1, OPRM1 | KDM4E 428/4885ALOX15 2490/4885MAPT 1818/4885 |
| US-20150025100-A1 | FORMULATIONS FOR PARENTERAL DELIVERY OF COMPOUNDS AND USES THEREOF | OPRL1, OPRK1, OPRM1 | KDM4E 557/4885ALOX15 1371/4885MAPT 3070/4885 |
| US-20080070975-A1 | Formulations for parenteral delivery of compounds and uses thereof | OPRL1, OPRK1, OPRM1 | KDM4E 557/4885ALOX15 1371/4885MAPT 3070/4885 |
| US-20160338946-A1 | FORMULATIONS FOR PARENTERAL DELIVERY OF COMPOUNDS AND USES THEREOF | OPRL1, OPRK1, OPRM1 | KDM4E 557/4885ALOX15 1371/4885MAPT 3070/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.